The last decade has observed tremendous scientific discoveries that have led to a much needed progress in our understanding of the biology driving the myeloproliferative neoplasms (MPNs) and conferring their various phenotypes. The identification of molecular drivers of proliferation in MPNs necessitated a novel, molecularly-derived classification of these neoplasms. Furthermore, as our understanding of non-driver mutations and their impact on prognosis of MPNs evolves, we need to develop strategies to identify high-risk patients and incorporate available therapies, including stem cell transplantation into treatment algorithms.
Dr. Francesco Passamonti will describe the new diagnostic criteria of the WHO classification for polycythemia vera, essential thrombocythemia, and myelofibrosis. He will discuss strategies to recognize MPNs and distinguish them from reactive conditions. He will introduce driver mutations including JAK2, MPL and CALR, and bone marrow histopathological findings that will help distinguish the three MPN entities.
Dr. Vikas Gupta will explore the clinical considerations involved in hematopoietic stem cell transplant (HCT) for myelofibrosis. He will discuss the questions of “who are the suitable candidates for HCT?”, “when is the optimal time for HCT?”, and “how to integrate JAK inhibitor therapy in transplant protocols.” He will also explore current controversies, provide recommendations for selection of patients, and highlight areas of unmet need for future research.
Dr. Shammo will describe the current mutational landscape of myeloproliferative neoplasms. She will discuss the prognostic implications and therapeutic relevance of driver and non-driver mutations concluding with a glimpse into the future of mutational profiling of MPNs.